Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)

Autor: Daniel J. George, Neeraj Agarwal, Oliver Sartor, Cora N. Sternberg, Bertrand Tombal, Fred Saad, Kurt Miller, Niculae Constantinovici, Helen Guo, John Reeves, XiaoLong Jiao, Per Sandström, Frank Verholen, Celestia S. Higano, Neal Shore
Přispěvatelé: UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie
Rok vydání: 2022
Předmět:
Zdroj: Prostate Cancer and Prostatic Diseases, Vol. 25, no. 2, p. 306-313 (2022)
ISSN: 1476-5608
1365-7852
DOI: 10.1038/s41391-021-00488-0
Popis: Background The real-world EPIX study was conducted to gather information about the characteristics of patients with metastatic castration-resistant prostate cancer (mCRPC) who survived ≥2 years after treatment with the alpha-emitter radium-223. Methods This retrospective study of electronic health records in the US Flatiron database (NCT04516161) included patients with mCRPC treated with radium-223 between January 2013 and June 2019. Median overall survival (OS) and prostate-specific antigen (PSA) response (≥50% reduction) from start of radium-223 treatment were the primary and secondary endpoints, respectively. Patient characteristics were compared between those who survived ≥2 years versus Results In the 1180 patients identified, median OS was 12.9 months (95% CI: 12.1–13.7), and 13% of patients with data at 6 months had a PSA response. The survival groups included 775 patients (65.7%) who survived 75 years, Eastern Cooperative Oncology Group performance status (ECOG PS) 2–4, visceral metastases, prior symptomatic skeletal events (SSEs), and prior chemotherapy were independently prognostic of reduced OS. For patients with survival ≥2 years versus Conclusions In this study of men with mCRPC treated in real-world clinical practice, median OS was consistent with that seen in the phase 3 ALSYMPCA trial. Patients who survived ≥2 years after the start of radium-223 were younger and had better ECOG PS, lower disease burden, and less use of prior chemotherapy than those who survived
Databáze: OpenAIRE
Externí odkaz: